The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
IMPACT trial: Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma.
Jorge Riera-Knorrenschild
No relevant relationships to disclose
Werner Scheithauer
No relevant relationships to disclose
Hendrik Kröning
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Dieter Nitsche
No relevant relationships to disclose
Reinhard Ziebermayr
No relevant relationships to disclose
Johannes Andel
No relevant relationships to disclose
Dirk Arnold
No relevant relationships to disclose
Burghardt Wittig
Consultant or Advisory Role - MOLOGEN
Stock Ownership - MOLOGEN
Hans-Joachim Schmoll
No relevant relationships to disclose